FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148045371> ?p ?o ?g. }

• W2148045371 endingPage "337" @default.
• W2148045371 startingPage "329" @default.
• W2148045371 abstract "To evaluate the safety and explore the efficacy of idursulfase (recombinant human iduronate-2-sulfatase) treatment for mucopolysaccharidosis II (MPS II). Twelve patients were enrolled into a randomized, double-blind, placebo-controlled trial for 24 weeks followed by an open-label extension study. Three groups of 4 patients were enrolled sequentially, with 3 patients in each group receiving idursulfase and 1 patient receiving placebo. The first group received idursulfase at 0.15 mg/kg infused every other week with the 2nd and 3rd groups receiving 0.5 and 1.5 mg/kg, respectively. After 24 weeks the placebo-treated patients were changed to idursulfase at the dose of their group. The primary endpoint was a change from baseline in urinary excretion of glycosaminoglycans. Results were pooled for analysis by ANOVA and compared to baseline. Urinary glycosaminoglycans were reduced within 2 weeks of initiating idursulfase and were decreased 49% after 48 weeks of treatment (P < 0.0001). Both liver and spleen volume were decreased at 24 weeks (P < 0.01) and 48 weeks (P < 0.001). The 6-minute walk test distance increased an average of 48 meters after 48 weeks (P = 0.013). Six patients in the higher dose groups developed IgG antibodies that did not influence the clinical effects of idursulfase. This study describes the first experience with enzyme replacement therapy for the treatment of patients with MPS II. Idursulfase was generally well tolerated and was associated with reductions in urine glycosaminoglycans levels and organ size, as well as an increased 6-minute walk test distance." @default.
• W2148045371 created "2016-06-24" @default.
• W2148045371 creator A5003186283 @default.
• W2148045371 creator A5032043915 @default.
• W2148045371 creator A5052111462 @default.
• W2148045371 creator A5085315279 @default.
• W2148045371 creator A5085890187 @default.
• W2148045371 date "2007-03-01" @default.
• W2148045371 modified "2023-10-18" @default.
• W2148045371 title "A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)" @default.
• W2148045371 cites W1510790224 @default.
• W2148045371 cites W1571262084 @default.
• W2148045371 cites W1930879781 @default.
• W2148045371 cites W1968758382 @default.
• W2148045371 cites W1969382234 @default.
• W2148045371 cites W1971558863 @default.
• W2148045371 cites W1975183928 @default.
• W2148045371 cites W1980743876 @default.
• W2148045371 cites W1993027304 @default.
• W2148045371 cites W1993518098 @default.
• W2148045371 cites W2022356406 @default.
• W2148045371 cites W2024590298 @default.
• W2148045371 cites W2041158844 @default.
• W2148045371 cites W2042946480 @default.
• W2148045371 cites W2043714135 @default.
• W2148045371 cites W2059320901 @default.
• W2148045371 cites W2093722439 @default.
• W2148045371 cites W2136255603 @default.
• W2148045371 cites W2140806188 @default.
• W2148045371 cites W2144194006 @default.
• W2148045371 cites W2149522829 @default.
• W2148045371 cites W2149949469 @default.
• W2148045371 cites W2152901044 @default.
• W2148045371 cites W2159466305 @default.
• W2148045371 cites W2165934664 @default.
• W2148045371 cites W2167018562 @default.
• W2148045371 cites W2312413018 @default.
• W2148045371 cites W2313827278 @default.
• W2148045371 cites W2322128806 @default.
• W2148045371 cites W2994597783 @default.
• W2148045371 cites W3141448427 @default.
• W2148045371 cites W4245666729 @default.
• W2148045371 doi "https://doi.org/10.1016/j.ymgme.2006.09.001" @default.
• W2148045371 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17185020" @default.
• W2148045371 hasPublicationYear "2007" @default.
• W2148045371 type Work @default.
• W2148045371 sameAs 2148045371 @default.
• W2148045371 citedByCount "191" @default.
• W2148045371 countsByYear W21480453712012 @default.
• W2148045371 countsByYear W21480453712013 @default.
• W2148045371 countsByYear W21480453712014 @default.
• W2148045371 countsByYear W21480453712015 @default.
• W2148045371 countsByYear W21480453712016 @default.
• W2148045371 countsByYear W21480453712017 @default.
• W2148045371 countsByYear W21480453712018 @default.
• W2148045371 countsByYear W21480453712019 @default.
• W2148045371 countsByYear W21480453712020 @default.
• W2148045371 countsByYear W21480453712021 @default.
• W2148045371 countsByYear W21480453712022 @default.
• W2148045371 countsByYear W21480453712023 @default.
• W2148045371 crossrefType "journal-article" @default.
• W2148045371 hasAuthorship W2148045371A5003186283 @default.
• W2148045371 hasAuthorship W2148045371A5032043915 @default.
• W2148045371 hasAuthorship W2148045371A5052111462 @default.
• W2148045371 hasAuthorship W2148045371A5085315279 @default.
• W2148045371 hasAuthorship W2148045371A5085890187 @default.
• W2148045371 hasConcept C126322002 @default.
• W2148045371 hasConcept C126894567 @default.
• W2148045371 hasConcept C141071460 @default.
• W2148045371 hasConcept C142724271 @default.
• W2148045371 hasConcept C203092338 @default.
• W2148045371 hasConcept C204787440 @default.
• W2148045371 hasConcept C27081682 @default.
• W2148045371 hasConcept C2776225084 @default.
• W2148045371 hasConcept C2779134260 @default.
• W2148045371 hasConcept C2779969927 @default.
• W2148045371 hasConcept C2910638406 @default.
• W2148045371 hasConcept C535046627 @default.
• W2148045371 hasConcept C71924100 @default.
• W2148045371 hasConcept C77411442 @default.
• W2148045371 hasConcept C90924648 @default.
• W2148045371 hasConceptScore W2148045371C126322002 @default.
• W2148045371 hasConceptScore W2148045371C126894567 @default.
• W2148045371 hasConceptScore W2148045371C141071460 @default.
• W2148045371 hasConceptScore W2148045371C142724271 @default.
• W2148045371 hasConceptScore W2148045371C203092338 @default.
• W2148045371 hasConceptScore W2148045371C204787440 @default.
• W2148045371 hasConceptScore W2148045371C27081682 @default.
• W2148045371 hasConceptScore W2148045371C2776225084 @default.
• W2148045371 hasConceptScore W2148045371C2779134260 @default.
• W2148045371 hasConceptScore W2148045371C2779969927 @default.
• W2148045371 hasConceptScore W2148045371C2910638406 @default.
• W2148045371 hasConceptScore W2148045371C535046627 @default.
• W2148045371 hasConceptScore W2148045371C71924100 @default.
• W2148045371 hasConceptScore W2148045371C77411442 @default.
• W2148045371 hasConceptScore W2148045371C90924648 @default.
• W2148045371 hasIssue "3" @default.
• W2148045371 hasLocation W21480453711 @default.

• next